AUSTIN (AP) _ Texas A&M University has been awarded one of three national biodefense contracts to help the country quickly develop vaccines in the event of a pandemic and strategies for responding to bioterrorism.
The contract was announced Monday by Texas A&M System Chancellor John Sharp and federal health officials.
The initial five-year contract is worth $176 million and can be renewed for up to 25 years. Texas A&M will partner with Georgia-based pharmaceutical giant GlaxoSmithKline and Kalon Biotherapeutics in College Station.
The biodefense center will work to develop vaccines to rapidly respond and protect against flu pandemics as well as research and training for response to chemical, biological, radiological and nuclear threats.